A Phase 2, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 May 2018
At a glance
- Drugs Capecitabine (Primary) ; Varlitinib (Primary)
- Indications Biliary cancer; Biliary tract disorders
- Focus Biomarker; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 21 May 2018 Planned initiation date changed from 1 Jul 2017 to 1 May 2018.
- 21 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Apr 2017 New trial record